Characterizing VEXAS syndrome in women: Findings from an international multicenter study
Journal of Internal Medicine · 2025-11 · 298 (5) · 516-524
DOI: 10.1111/joim.70023 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Internal Medicine, online erschienen am 23.09.2025. Verfasst von Rim Bourguiba und 18 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Tenon Hospital, Sorbonne University, DMU 3iD, CEREMAIA, ERN RITA, Paris, France. Hauptthemen laut MEDLINE: Ubiquitin-Activating Enzymes, Hereditary Autoinflammatory Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
Background
VEXAS syndrome is an autoinflammatory disease caused by somatic UBA1 mutations on the X chromosome, predominantly affecting men.
Objective
To characterize VEXAS syndrome in women and to compare the features of VEXAS syndrome between sexes.
Methods
We conducted an international, multicenter study, including 12 women and 301 men with genetically confirmed VEXAS syndrome. Data were collected using a standardized case report form. Bone marrow analyses and molecular investigations were performed locally.
Results
Clinical features, age at onset, UBA1 mutation type, variant allele frequency, and mortality were comparable between sexes. Acquired X monosomy was found in 6/8 tested women. Additional clonal mutations were present in 3/5 tested women. Three additional UBA1 ‐mutated women without typical inflammation are described separately.
Conclusion
VEXAS syndrome affects women with clinical features similar to men, supporting the need for UBA1 testing in women with compatible presentations. X monosomy is common but not universal, suggesting alternative pathogenic mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine Department, Tenon Hospital, Sorbonne University, DMU 3iD, CEREMAIA, ERN RITA, Paris, France.
- Faculté de Medecine de Tunis, Université Tunis el Manar, Department of internal medicine, Hopital des Forces de securité interiure, La Marsa, Tunisie.
- Service de Médecine Interne Et Polyvalente, Centre Hospitalier du Haut-Anjou, Château-Gontier-sur-Mayenne, France.
- Univ Angers, Inserm, CNRS, MITOVASC, Equipe MitoLab, SFR ICAT, Angers, France.
- Center for Human Genetics and Genomics, New York University Grossman School of Medicine, New York, New York, USA.
- Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
ORCID-Profile: Valentin Lacombe, David Beck, Thibault Comont, Mael Heiblig, Yohei Kirino, Arsene Mekininan, Sophie Georgin-Lavialle
Zitieren
APA
Bourguiba, R., Lacombe, V., Beck, D., Martín-Nares, E., Jachiet, V., Comont, T., Galland, J., Heiblig, M., Nguyen, A., Aouba, A., Boulu, X., Curie, A., Terrier, B., Bescond, C., Koster, M., Kirino, Y., Kosmider, O., Mekininan, A., & Georgin-Lavialle, S. (2025). Characterizing VEXAS syndrome in women: Findings from an international multicenter study. Journal of Internal Medicine, 298(5), 516-524. https://doi.org/10.1111/joim.70023
Vancouver
Bourguiba R, Lacombe V, Beck D, Martín-Nares E, Jachiet V, Comont T, et al. Characterizing VEXAS syndrome in women: Findings from an international multicenter study. Journal of Internal Medicine. 2025;298(5):516-524. doi:10.1111/joim.70023
BibTeX
@article{Bourguiba2025,
author = {Bourguiba, Rim and Lacombe, Valentin and Beck, David and Martín-Nares, Eduardo and Jachiet, Vincent and Comont, Thibault and Galland, Joris and Heiblig, Mael and Nguyen, Alexandre and Aouba, Achille and Boulu, Xavier and Curie, Alexandre and Terrier, Benjamin and Bescond, Charles and Koster, Matthew and Kirino, Yohei and Kosmider, Olivier and Mekininan, Arsene and Georgin-Lavialle, Sophie},
title = {Characterizing VEXAS syndrome in women: Findings from an international multicenter study},
journal = {Journal of Internal Medicine},
year = {2025},
volume = {298},
number = {5},
pages = {516--524},
doi = {10.1111/joim.70023}
}
EUVIMED